Related Experiment Video

Updated: Jun 3, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Home IV Antibiotic Therapy and Exercise Capacity in Children with CF: A Case Series

Narelle S Cox1, Karen O McKay, Jennifer M Follett

  • 1Department of Physiotherapy, The Children's Hospital at Westmead, Sydney, Australia.

Cardiopulmonary Physical Therapy Journal
|March 31, 2011
PubMed

Insights

Home intravenous (IV) antibiotic therapy improved lung function (spirometry) in children with cystic fibrosis (CF). However, exercise capacity did not show significant improvement in this study.

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases in Cystic Fibrosis
  • Respiratory Medicine

Background:

  • Cystic Fibrosis (CF) exacerbations often require intravenous (IV) antibiotics.
  • Home IV antibiotic therapy offers a convenient alternative to hospital admission.
  • The impact of home IV antibiotics on functional outcomes like exercise capacity in pediatric CF patients requires further understanding.

Purpose of the Study:

  • To evaluate the effect of a 14-day course of home IV antibiotic therapy on spirometry and exercise capacity.
  • To assess changes in lung function and physical performance in children with CF undergoing home IV antibiotic treatment.

Main Methods:

  • A case series of 10 children with CF receiving 14-day home IV antibiotics for respiratory exacerbations.
  • Spirometry and the modified shuttle test (MST) were performed before and after the 14-day treatment period.
  • Analysis focused on changes in FEV(1) and MST distance.

Main Results:

  • A statistically significant mean increase of 12% in FEV(1) was observed post-treatment (p < 0.05).
  • All participants maintained or improved their spirometry values.
  • No significant improvement in mean MST distance was noted, with only 5 out of 10 children showing improvement.

Conclusions:

  • Home IV antibiotic therapy led to significant improvements in spirometry for children with CF.
  • Exercise capacity, as measured by MST, did not consistently improve, suggesting other factors influence physical performance.
  • Further research is needed to identify factors affecting exercise capacity during home IV antibiotic treatment in CF.
Abstract

Keywords:
FEV1Modified Shuttle Testcystic fibrosishome IV therapy

More Related Videos

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.